BHC
Bausch Health Companies Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$6.56
−2.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.9B | 10.3B | 9.6B | 8.8B | 8.1B |
| Cost of Revenue | 3.1B | 3.0B | 2.8B | 2.6B | 2.4B |
| Gross Profit | 7.8B | 7.3B | 6.8B | 6.2B | 5.8B |
| Operating Expenses | |||||
| R&D Expense | 634.0M | 629.0M | 634.0M | 604.0M | 530.0M |
| SG&A Expense | 3.4B | 3.4B | 3.3B | 2.9B | 2.5B |
| General & Admin Expense | — | — | 2.5B | 2.3B | 2.0B |
| Selling & Marketing Expense | — | — | 786.0M | 625.0M | 518.0M |
| Other Expenses | 955.0M | 1.0B | 1.4B | 1.7B | 2.2B |
| Total Operating Expenses | 5.0B | 5.1B | 5.3B | 5.2B | 5.3B |
| Cost and Expenses | 8.1B | 8.1B | 8.1B | 7.8B | 7.7B |
| Operating Income (EBIT) | 2.8B | 2.2B | 1.5B | 963.0M | 454.0M |
| Non-Operating | |||||
| Interest Income | 45.0M | 48.0M | 33.0M | 26.0M | 14.0M |
| Interest Expense | 1.6B | 1.6B | 1.4B | 1.3B | 1.5B |
| Net Interest Income | (1.6B) | (1.6B) | (1.4B) | (1.3B) | (1.4B) |
| Other Non-Op Income/Expense | (3.5B) | (1.8B) | (1.4B) | (1.4B) | (583.0M) |
| Non-Operating Income (excl Interest) | 1.9B | 214.0M | (321.0M) | (658.0M) | (1.0B) |
| EBT (Pre-Tax Income) | (732.0M) | 367.0M | 167.0M | (390.0M) | (129.0M) |
| Income Tax Expense | 361.0M | 247.0M | 239.0M | 221.0M | 83.0M |
| Bottom Line | |||||
| Net Income | (1.1B) | 157.0M | (46.0M) | (592.0M) | (225.0M) |
| Earnings from Cont. Ops | (1.1B) | 120.0M | (72.0M) | (611.0M) | (212.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.1B) | 157.0M | (46.0M) | (592.0M) | (225.0M) |
| Per Share | |||||
| Basic EPS | ($2.95) | $0.43 | ($0.13) | ($1.62) | ($0.62) |
| Diluted EPS | ($2.95) | $0.43 | ($0.13) | ($1.62) | ($0.62) |
| Revenue Per Share | $28.94 | $27.68 | $26.15 | $24.00 | $22.44 |
| Shares | |||||
| Basic Shares Outstanding | 375.0M | 370.9M | 368.0M | 364.9M | 362.0M |
| Diluted Shares Outstanding | 378.1M | 375.0M | 368.0M | 364.9M | 362.0M |
| Profitability Metrics | |||||
| EBITDA | 2.0B | 3.2B | 3.1B | 2.9B | 2.9B |
| D&A | 1.2B | 1.2B | 1.3B | 1.3B | 1.4B |
| EBIT | 875.0M | 2.0B | 1.9B | 1.6B | 1.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026